{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72","upperLimit":"88","value":"80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"}],"units":"Participants"}],"description":"The primary efficacy endpoint and analysis for this study was the percentage of LPCN 1021 treated subjects who had achieved a 24-hour average serum T concentration within the normal range of 300 to 1080 ng/dL at Visit 4, (Day 24 ± 4 days).","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.\n\nLPCN 1021: Oral testosterone undecanoate","id":"OG000","title":"Oral Testosterone Undecanoate, LPCN 1021"}],"paramType":"NUMBER","populationDescription":"Safety Set","reportingStatus":"POSTED","timeFrame":"Following 24 days of treatment","title":"Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal Range","type":"PRIMARY","unitOfMeasure":"Percent of participants"}